Abstract
Immune checkpoint inhibitors (ICIs) have been changing the paradigm of cancer treatment. However, immune-related adverse effects (irAEs) have also increased with the exponential increase in the use of ICIs. ICIs can break up the immunologic homeostasis and reduce T-cell tolerance. Therefore, inhibition of immune checkpoint can lead to the activation of autoreactive T-cells, resulting in various irAEs similar to autoimmune diseases. Gastrointestinal toxicity, endocrine toxicity, and dermatologic toxicity are common side effects. Neurotoxicity, cardiotoxicity, and pulmonary toxicity are relatively rare but can be fatal. ICI-related gastrointestinal toxicity, dermatologic toxicity, and hypophysitis are more common with anti-CTLA-4 agents. ICI-related pulmonary toxicity, thyroid dysfunction, and myasthenia gravis are more common with PD-1/PD-L1 inhibitors. Treatment with systemic steroids is the principal strategy against irAEs. The use of immune-modulatory agents should be considered in case of no response to the steroid therapy. Treatment under the supervision of multidisciplinary specialists is also essential, because the symptoms and treatments of irAEs could involve many organs. Thus, this review focuses on the mechanism, clinical presentation, incidence, and treatment of various irAEs.

Keywords: Immune checkpoint inhibitor; Adverse events; Programmed cell death 1

Introduction
Immunotherapy has opened up new horizons for cancer treatment (1). In particular, immune checkpoint inhibitors (ICIs) for CTLA-4 and PD-1/PD-L1 pathways have been used to treat various solid cancers. Currently, Food and Drug Administration approved ICIs include anti-CTLA-4 (ipilimumab), PD-1 inhibitors ( pembrolizumab and nivolumab), and PD-L1 inhibitors (atezolizumab, durvalumab, and avelumab). The superiority of the effects of these drugs has been demonstrated, compared to conventional cytotoxic chemotherapy, although various side effects are present. Recently, combination therapy with various ICIs and cytotoxic chemotherapy has been initiated and various side effects are expected (2).

Frequent immune-related adverse events (irAEs) include gastrointestinal, endocrine, and dermatologic toxicities. Fatal irAEs include neurotoxicity, cardiotoxicity, and pulmonary...
IrAEs are evaluated and treated using the Common Terminology Criteria for Adverse Events, European Society for Medical Oncology guideline and American Society of Clinical Oncology guideline (Tables 1 and 2) (5–7). Treatment for grade 1 toxicity is conservative and maintenance of ICIs therapy is considered based on symptoms and involved organs. ‘Hold immunotherapy’ and oral prednisone treatment should be considered in grade 2 toxicity. In grade 3 or 4 toxicity, ICIs should be discontinued, and higher doses of systemic steroids should be considered. If patients do not respond to steroids, immunomodulatory therapy should be initiated. If systemic steroid and immunomodulatory therapy do not improve symptoms, intravenous immunoglobulin or plasmapheresis treatment should be considered in fatal irAEs. Retrying ICIs therapy is not recommended until the irAE has improved to grade 1 or the symptoms have disappeared. In case of fatal irAEs or grade 4 irAEs, retrying ICIs therapy is not recommended. Some irAEs have been reported to be associated with a favorable clinical outcome, but this is

<table>
<thead>
<tr>
<th>The organ(s)</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute kidney injury (Cr increased)</td>
<td>1.0–1.5 × ULN</td>
<td>1.5–3.0 × ULN 1.5–3.0 × baseline</td>
<td>3.0–6.0 × ULN &gt;3.0 × baseline</td>
<td>&gt;6.0 × ULN Dialysis indicated</td>
</tr>
<tr>
<td>Inflammatory arthritis</td>
<td>- Mild pain with inflammation, erythema, or joint swelling - Increase of fewer than 4 stools per day</td>
<td>- Moderate pain with inflammation, erythema, or joint swelling - Limiting instrumental ADL</td>
<td>- Severe pain with inflammation, erythema, or joint swelling - Irreversible joint damage - Limiting self-care ADL</td>
<td>- Life-threatening consequences signs - Change in bowel habit - Increase of seven or more stools per day</td>
</tr>
<tr>
<td>Colitis</td>
<td>- Asymptomatic</td>
<td>- Abdominal pain - Mucus or blood in stool - Increase of four to 6 stools per day</td>
<td>- Severe abdominal pain peritoneal signs</td>
<td>- Life-threatening consequences</td>
</tr>
<tr>
<td>Hepatitis (AST, ALT increased)</td>
<td>&lt;3.0 × ULN</td>
<td>3.0–5.0 × ULN</td>
<td>5.0–20.0 × ULN</td>
<td>&gt;20.0 × ULN</td>
</tr>
<tr>
<td>Hypophysitis</td>
<td>- Asymptomatic or mild symptoms</td>
<td>- Moderate symptoms limiting age-appropriate instrumental ADL</td>
<td>- Severe or medically significant limiting self-care ADL</td>
<td>- Life-threatening consequences (visual field impairment)</td>
</tr>
<tr>
<td>Skin rash</td>
<td>- Target lesions covering ≤10% BSA and not associated with skin tenderness</td>
<td>- Target lesions covering 10%–30% BSA and associated with skin tenderness</td>
<td>- Target lesions covering &gt;30% BSA</td>
<td>- Severe/life-threatening symptoms - Generalized exfoliative/ulcerated/bullous rash</td>
</tr>
</tbody>
</table>

Cr, creatinine; ULN, upper limit normal; ADL, activity of daily living; BSA, body surface area; EKG, electrocardiogram.
still controversial (8). ICIs can be used cautiously in most patients with comorbidities, but it is dangerous for solid-organ transplant patients (9). In this review, we describe the mechanism, clinical presentation, incidence, and treatment based on the organ(s) affected by the irAEs, such as abdomen, endocrine organ, joint and skin, nervous system, and thorax.

Table 2. Management of irAEs (European Society for Medical Oncology guideline, American Society of Clinical Oncology guideline)

<table>
<thead>
<tr>
<th>The organ(s)</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute kidney injury</td>
<td>- Consider ‘Hold immunotherapy’</td>
<td>- Hold immunotherapy</td>
<td>- Permanently discontinue immunotherapy</td>
<td>- IV methylprednisone 1–2 mg/kg/day</td>
</tr>
<tr>
<td></td>
<td>- Hydration</td>
<td>- Oral prednisone 0.5–1 mg/kg/day</td>
<td>- Oral prednisone 1–2 mg/kg/day</td>
<td>- Start dialysis</td>
</tr>
<tr>
<td></td>
<td>- Check and stop nephrotoxic drug (PPI or NSAIDs)</td>
<td>- A nephrology consultation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammatory arthritis</td>
<td>- Continue immunotherapy</td>
<td>- Consider ‘Hold immunotherapy’</td>
<td>- Hold immunotherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- NSAs (eg, ibuprofen) or acetaminophen</td>
<td>- Oral prednisone 0.5-10 mg/day</td>
<td>- Oral prednisone 0.5–1 mg/kg/day</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Intra-articular steroid injection</td>
<td>- A rheumatology consultation</td>
<td>- Consider immunomodulatory therapy (DMARDs) in steroid non-responders</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colitis</td>
<td>- Continue immunotherapy</td>
<td>- Consider ‘Hold immunotherapy’</td>
<td>- Hold immunotherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Oral fluids</td>
<td>- Oral prednisone 0.5-1 mg/kg/day</td>
<td>- Oral prednisone 1–2 mg/kg/day</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Antidiarrheal agents (eg, loperamide)</td>
<td>- Consider sigmoidoscopy/colonoscopy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Avoid high fibre/lactose diet</td>
<td>- A gastroenterology consultation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis</td>
<td>- Continue immunotherapy</td>
<td>- Hold immunotherapy</td>
<td>- Permanently discontinue immunotherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Check hepatotoxic drug</td>
<td>- Oral prednisone 0.5-1 mg/kg/day</td>
<td>- IV methylprednisone 1–2 mg/kg/day</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Consider immunomodulatory therapy (mycophenolate mofetil, azathioprine or tacrolimus) in steroid non-responders</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Do not offer infliximab</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- A hepatology consultation</td>
<td></td>
</tr>
<tr>
<td>Hypophysitis</td>
<td>- Consider ‘Hold immunotherapy’</td>
<td>- Consider ‘Hold immunotherapy’</td>
<td>- Hold immunotherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Start glucocorticoid replacement with stress day rules (e.g., hydrocortisone 10–20 mg orally in the morning, 5–10 mg orally in early afternoon, levodopa by weight)</td>
<td>- Oral prednisone 0.5-1 mg/kg/day</td>
<td>- Oral prednisone 1–2 mg/kg/day</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- An endocrinology consultation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin rash</td>
<td>- Continue immunotherapy</td>
<td>- Consider ‘Hold immunotherapy’</td>
<td>- Hold immunotherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Topical emollients</td>
<td>- Oral prednisone 1 mg/kg/day</td>
<td>- A dermatology consultation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Topical corticosteroids</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Oral antihistamines for pruritus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatal adverse effects</td>
<td>Myasthenia gravis</td>
<td>- Continue immunotherapy</td>
<td>- Permanently discontinue immunotherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Monitor symptoms for progression</td>
<td>- Oral prednisone 1-1.5 mg/kg/day</td>
<td>- IV methylprednisone 1–2 mg/kg/day</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Pyridostigmine starting at 30 mg orally three times a day</td>
<td>- Consider IVIG or plasmapheresis in steroid non-responders</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Consider immunomodulatory therapy (azathioprine, cyclosporine, mycophenolate) in steroid non-responders</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- A neurology consultation</td>
<td></td>
</tr>
<tr>
<td>Myocarditis</td>
<td>- Hold or permanently discontinue immunotherapy at any sign of cardiotoxicity</td>
<td>- Hold immunotherapy</td>
<td>- Permanently discontinue immunotherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Oral prednisone 1-2 mg/kg/day</td>
<td>- IV methylprednisone 1–2 mg/kg/day</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Pyridostigmine starting at 30 mg orally three times a day</td>
<td>- Consider IVIG or plasmapheresis in steroid non-responders</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Consider immunomodulatory therapy (azathioprine, cyclosporine, mycophenolate) in steroid non-responders</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- A neurology consultation</td>
<td></td>
</tr>
<tr>
<td>Pneumonitis</td>
<td>- Hold immunotherapy</td>
<td>- oral prednisone 1-2 mg/kg/day</td>
<td>- Permanently discontinue immunotherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Consider empirical antibiotics</td>
<td>- IV methylprednisone 1–2 mg/kg/day</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Consider bronchoscopy and/or BAL</td>
<td>- Empirical antibiotics</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Consider additional immunomodulatory therapy (infliximab 5–10 mg/kg, mycophenolate mofetil or tacrolimus) IV 1 g twice a day or cyclosporamide)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Consider IVIG if there is no improvement</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- A pulmonology consultation</td>
<td></td>
</tr>
</tbody>
</table>

DMARD, disease-modifying anti-rheumatic drug; IVIG, intravenous immunoglobulin; BAL, bronchoalveolar lavage.
MECHANISM OF IRAES

ICIs block inhibitory checkpoint and activate T-cell mediated immune response. The precise mechanism of irAEs is still unknown, but several hypotheses are suggested. The key idea is that the use of ICIs breaks up the immunologic homeostasis and reduces T-cell tolerance (10). There is some cross-reactivity of T-cells between tumor cells and normal tissue (11). ICIs can increase levels of preexisting autoantibodies, such as antithyroid Abs (12). ICIs can also increase the level of inflammatory cytokines. In organs that express CTLA-4 or PD-L1 directly to protect normal tissue, such as in normal pituitary cells or cardiomyocytes, ICI can disturb these self-protect system (13,14). Due to these various reasons, activated T-cells attack healthy tissue, resulting in irAEs with features similar to autoimmune diseases.

ABDOMEN

Gastrointestinal tract

Clinical presentation and diagnosis

Gastrointestinal toxicity is a common side effect of ICIs. Nausea, vomiting, dysphagia, and epigastric pain may occur when the side effects involve the upper gastrointestinal tract; abdominal pain, hematochezia, and diarrhea may occur when the side effects involve the lower gastrointestinal tract. Lower gastrointestinal tract toxicity occurs more often than upper gastrointestinal tract toxicity. However, asymptomatic or non-specific symptom, which is not related to gastrointestinal symptoms, is also common (Fig. 1A and B). Endoscopy is helpful in diagnosing ICI-induced colitis and the assessment of therapeutic response (15). Stool analysis for bacterial pathogens and clostridium difficile toxin should be considered for differential diagnosis.

Incidence

Generally, anti-CTLA-4 agents are known to show higher incidence and severity of gastrointestinal side effects than those shown by PD-1/PD-L1 inhibitors (16,17). The incidence of side effects is higher in ICIs combination therapy than in ICIs monotherapy (4); moreover, the onset of the side effects is faster (18,19) and occurs 6–8 weeks after the start of ICIs treatment. In the case of anti-CTLA-4 agents, side effects can occur several months after the drug is discontinued. This is because the molecular effects of anti-CTLA-4 agents that are maintained after drug clearance (20).

Figure 1. Enterocolitis related to immune checkpoint inhibitors. (A) Before steroid treatment, axial contrast computed tomography scan shows wall thickening and abnormal enhancement in intestine. (B) After steroid treatment, intestinal wall thickening and abnormal enhancement are reduced.
**Treatment strategies**

The first choice of treatment is a systemic steroid (oral prednisone 0.5–1 mg/kg/day) (21). Infliximab (anti-TNF-α) may be considered for patients that do not respond to systemic steroids (22). Recently, the use of vedolizumab (a humanized monoclonal IgG1 Ab against α4β7 integrin) has also been reported to be effective in some case reports and case series (23). A gastroenterology consultation is needed for toxicities above grade 2. Hydration, electrolyte replacement, and antidiarrheal agents should be considered for conservative care.

**Gut microbiota**

The gut microbiota has been actively studied as a factor affecting gastrointestinal toxicity (24,25). Particular bacterial populations in the gut have been found to be associated with ICI-induced colitis (26); moreover, repeated antibiotic use is considered a risk factor for ICI-related gastrointestinal toxicity. ICIs can increase gut permeability or damage the gut epithelium. Damage of epithelium can cause the gut microbiota to enter the bloodstream, thereby affecting and changing the immune system (24,27). Some cases of fecal microbiota transplantation have been reported in patients who did not respond to systemic steroids or infliximab (28).

**Hepatitis**

**Clinical presentation and diagnosis**

If aspartate aminotransferase (AST) or alanine aminotransferase (ALT) is more than 2-fold higher than upper limit normal, tests related to hepatitis should be considered (29). Check other medications that cause hepatotoxicity and test for viral hepatitis and autoimmune hepatitis should be performed. Image tests should be undertaken to identify liver metastasis or biliary obstruction. Liver biopsy can be useful in the diagnosis of immune mediated hepatitis (IMH). Liver biopsy shows lobular hepatitis with abundant infiltration by CD3+ or CD8+ T-lymphocytes (30). Fibrin-ring granulomas are not absolute pathognomonic findings but can be estimated by IMH if identified (31).

**Incidence**

The incidence of ICI-associated IMH has been reported to be approximately 2%–15% in clinical trial (32). Anti-CTLA-4 agents are known to show higher incidence of IMH than PD-1/PD-L1 inhibitors. The incidence rates are higher in ICI combination therapy than in ICI monotherapy. Fortunately, the fatal case of IMH is relatively rare (17). Underlying chronic liver disease, such as chronic viral hepatitis or non-alcoholic steatohepatitis, are considered as risk factors (33). Although data are few and not available about antiviral treatment, there is a case report of hepatitis B virus reactivation during the ICI treatment (34).

**Treatment strategies**

Systemic steroid is the basis for the treatment of IMH. If patients do not respond to steroids, tacrolimus, mycophenolate mofetil or azathioprine should be initiated or added. However, infliximab (anti-TNF-α agent) should not be used because it can cause severe liver injury (35).

**Kidney**

**Clinical presentation and diagnosis**

Acute interstitial nephritis (AIN) is the most common immune-related nephrotoxicity pattern (36). Most drug-induced AIN is caused by drug hypersensitivity reactions (37). However, immune-related AIN is similar to autoimmune disease (38). Renal biopsies show tubular injury rather than glomerular injury and include features such as edema,
interstitial inflammation, and tubulitis. The renal interstitium shows infiltration of CD4+ and CD8+ lymphocytes, in addition to eosinophils and plasma cells. No deposition of specific immunoglobulins or complement fractions is observed. Urine studies often show sterile pyuria and white blood cell casts. Most other ICIs appear as typical tubulointerstitial nephritis, with only ipilimumab sometimes manifesting as nephrotic syndrome (39,40).

Incidence
Acute kidney injury (AKI), abnormal electrolytes, and severe AKI which need dialysis occur in approximately 2%, 1%, and 0.5% of cases, respectively (41). The incidence of AKI in ipilimumab and nivolumab combination therapy has been reported to be approximately 5% (42). However, the incidence rates mentioned above are based on clinical trials; there are case reports and unpublished cohort study data suggesting that approximately 10%-30% may occur in real clinical settings (43).

Treatment strategies
The basis of therapy is a systemic steroid in immune-related nephrotoxicity. If AKI occurs, clinicians should check the history of drug use and discontinue any medications that may cause kidney damage. If kidney damage occurs that requires dialysis, ICI should be immediately abrogated.

Mechanism
The cause of nephrotoxicity in ICI therapy can be explained by three mechanisms. First, the ICI breaks down peripheral tolerance to self-reactive T-lymphocytes (44). This phenomenon causes an autoimmune variant of interstitial nephritis. Second, the ICI activates drug-specific effector T-cells that are associated with the nephrotoxic drug (45). Several reports show that using proton pump inhibitor (PPI) or non-steroidal anti-inflammatory drug (NSAID) is a risk factor for nephrotoxicity in ICI users. It has also been reported that stopping PPI or NSAID can restore renal function in mild AKI without stopping ICI. There are case reports that PPI or NSAIDs may cause nephrotoxicity, in patients who have used PPI or NSAID for a long time without any nephrotoxicity (46). Thirdly, using ICI increases pro-inflammatory cytokines, which can produce new auto-antibodies that can cause kidney damage (41).

Kidney transplant patients
Although data are lacking, the risk of ICI use is emphasized in patients undergoing kidney transplantation (9,47). In a case report, 30%-60% of kidney rejections were identified in renal transplant patients. Most patients with rejection did not respond to systemic steroids, and transplant kidney damage was progressing or continuing, even despite ICI cancellation. Therefore, ICI should not be used in kidney transplant patients.

ENDOCRINE ORGANS

Endocrine toxicity
Clinical presentation and diagnosis
Endocrine toxicity is a very common irAE and includes hypophysitis, thyroid dysfunction, primary adrenal insufficiency, hypoparathyroidism, and type 1 diabetes mellitus (48). Hypophysitis and thyroid dysfunction are the most common endocrine toxicities (49). Endocrine toxicity is difficult to diagnose, because most symptoms, such as nausea, vomiting, appetite loss, weight loss, general weakness, fatigue, mild cognitive dysfunction,
hypotension, and headache, are nonspecific. Besides, the symptoms are similar to cancer progression or brain metastasis, resulting in delayed diagnosis. Delayed diagnosis can lead to fatal side effects, such as adrenal crisis, thyroid storm, severe hypocalcemia, and diabetic ketoacidosis (50). Endocrine toxicity is often diagnosed by routine laboratory surveillance under asymptomatic conditions. If the symptoms are caused by anti-CTLA-4 therapy, the side effects are dose-dependent (51). Hypophysitis, thyroid dysfunction, and adrenal insufficiency are significantly higher in ICI combination therapy than in ICI monotherapy (52).

**Treatment strategies**

While the treatment of other irAEs is based on systemic steroids, endocrine toxicity is based on the replacement of the deficient hormone. Moreover, other forms of immunomodulatory therapy are not recommended for treatment. Endocrine toxicity is often irreversible compared to other irAEs, because ICIs can cause permanent damage to the endocrine glands (53).

**Hypophysitis**

Hypophysitis is more common with anti-CTLA-4 than PD-1/PD-L1 inhibitors (52). Anti-CTLA-4 can cause direct damage to the pituitary gland, because pituitary cells express CTLA-4 (13). Usually, it occurs 4-10 weeks after ICI treatment (54). Toxicity occurs more often in men and older patients (55). Abnormal prolactin levels as well as growth hormone and posterior pituitary hormone deficiency is rare (56). Enlargement of the pituitary gland is rare in cases of ICI-induced hypophysitis (57). Therefore, diagnosis should be based on hormonal evaluation and clinical presentation, not image evaluation (58). Adrenocorticotropic hormone and cortisol tests, performed in the morning, are recommended for diagnosis. If the morning cortisol level is <350 nmol/L, the adrenocorticotropic hormone test should be conducted. If the morning cortisol level is <250 nmol/L or a random cortisol level is <150 nmol/L, hormone replacement therapy should be considered. In the presence of mass effect symptoms, such as a severe headache or visual field impairment, high-doses of glucocorticoids are considered (56).

**Thyroid**

Thyroid dysfunctions include hypothyroidism, hyperthyroidism, and thyroiditis. Thyroid dysfunction is more common with PD-1/PD-L1 inhibitors than with anti-CTLA-4. Moreover, hyperthyroidism is more common with PD-1 inhibitors than PD-L1 inhibitors (59). ICI-related thyroid dysfunctions are more common in females. Thyroglobulin auto-antibodies and/or anti-thyroid peroxidase Abs are reported to be potential biomarkers. Regular monitoring of thyroid-stimulating hormone and free thyroxine is recommended for at least 5–6 cycles of ICI therapy (60). Levothyroxine treatment is recommended when thyroid-stimulating hormone levels are >10 mU/L (61). Beta-blockers can be useful when symptoms of hyperthyroidism are observed (62).

**HEMATOLOGIC COMPLICATIONS**

Hematologic toxicities are rare irAEs. The risk of hematologic toxicities is lower in ICI than in cytotoxic chemotherapy. In a recent meta-analysis on PD-1 inhibitors, the incidence of all-grade anemia, thrombocytopenia, leukopenia, and neutropenia was 5%, 2%, 2%, and 1%, respectively (63). However, hematologic toxicities are fatal; for example, the mortality rate of immune thrombocytopenic purpura and hemolytic anemia exceeds 10% (64). Anti-CTLA-4
agent causes hematologic toxicity faster than PD-1/PD-L1 inhibitors (65). Systemic steroids are the core of treatment, and transfusion should be performed as supportive care. However, research regarding hematologic complications is still scarce compared to other irAEs.

**JOINT AND SKIN**

**Joint**

*Clinical presentation and diagnosis*

Clinical symptoms include joint swelling, warmth, erythema, or recently experienced joint pain. Erosive joint damage or change can progress rapidly. Evaluating joint erosion through sonography or magnetic resonance imaging may be helpful in diagnosis ([Fig. 2](https://doi.org/10.4110/in.2020.20.e9)). If diagnosis is delayed and joint deformities develop, permanent motion limitation or chronic symptoms may occur. If a suspected symptom occurs, it is vital to early diagnose and treat the disease, in consultation with a rheumatologist. Compared to other irAEs, side effect is chronic and persistent and often requires long-term treatment.

*Incidence*

Representative irAEs associated with the joints are arthralgia, inflammatory arthritis, and tenosynovitis (66). In clinical trials, arthralgia is reported by 3%–7% and inflammatory arthritis by 1% of cases (67,68). High-risk factors are ICI combination therapy, long-term use of ICI, and previous occurrence of other irAEs. Occurrence of inflammatory arthritis is rare and later than other irAEs. Occasionally, inflammatory arthritis occurs after more than a year of stopping ICI treatment (69). In addition, compared to other symptoms, the diagnosis of inflammatory arthritis is often delayed because patients do not complain unless the doctor asks explicitly about joint pains.

*Treatment strategies*

Like in case of other irAEs, systemic steroids are used for treatment. Non-steroidal anti-inflammatory drugs (NSAIDs) and intra-articular steroid injections may be helpful for supportive management (70). For side effects above grade 3, immunomodulatory therapy, such as disease-modifying antirheumatic drugs, can prevent permanent damage (71). Although detailed studies are still lacking, it has been reported that immunomodulatory

![Figure 2. Inflammatory arthritis related to immune checkpoint inhibitors on both knees; axial contrast computed tomography scan show moderate joint effusion of both knees (right > left) with associated synovial thickening.](https://immunenetwork.org/)

https://immunenetwork.org
therapy does not affect treatment response (72,73). Moreover, some studies report that persistent arthritis is associated with a better treatment response.

**Skin**

*Clinical presentation and diagnosis*

The skin is known to be the most affected by enhanced autoimmunity; thus, dermatologic toxicity is the most common irAEs (74). Common symptoms include rash, pruritus, and vitiligo. Rashes mainly localize to the trunk and extremities and may be combined with pruritus (75). The head, palms, and soles are often affected later, and the rash mostly manifests as erythematosus macules, papules, and plaques (Fig. 3). Biopsy of the rash shows perivascular eosinophilic and leukocytic infiltrates (76). In severe cases, toxic epidermal necrolysis, Stevens-Johnson syndrome, vasculitis, and drug reaction with eosinophilia and systemic symptoms may occur (77). Sweet syndrome, cutaneous sarcoidosis, and bullous skin disorders have been reported very rarely (78).

*Incidence*

Dermatologic toxicity occurs faster than other irAEs (79); it is observed approximately 1 month after starting anti-CTLA-4 and approximately 2 months after starting PD-1/PD-L1 inhibitors (80). Dermatologic toxicity and severe toxicity are generally reported to occur in 25% and 2% of cases, respectively (81). Dermatologic toxicity occurs more frequently and severely with anti-CTLA-4 than PD-1/PD-L1 inhibitors. In anti-CTLA-4 therapy, dermatologic toxicity may be dose-dependent. It is more common in ICI combination therapy, and the main symptoms are rash and pruritus. Among the various symptoms of dermatologic toxicity, rash and vitiligo are suspected to be preferable marker for ICI treatment response (8,82).

*Treatment strategies*

In most cases, dermatologic toxicity is mild and can be treated with topical corticosteroids or antihistamines (grade 1) (83). Gabapentin, a neurokinin 1 receptor antagonist, and doxepin...

![Figure 3. Exacerbation of psoriasis under immune checkpoint inhibitors; plaque psoriasis with silvery scales on trunk.](https://doi.org/10.4110/in.2020.20.e9)
may help at severe pruritus (84). For side effects above grade 2, the use of oral prednisone at 1 mg/kg/day is recommended. If the condition of the patient continues to worsen while using systemic steroids, the use of additional immunomodulatory therapy, such as infliximab, cyclophosphamide, and mycophenolate mofetil, should be considered.

**NERVOUS SYSTEM**

**Neurotoxicity**

**Clinical presentation and diagnosis**

ICI-related neurotoxicity can be classified into inflammatory (encephalitis, myelitis, vasculitis, and meningitis) and peripheral neuromuscular autoimmune disorders (myasthenia gravis and Guillain-Barre syndrome). If ICI-related neurotoxicity is suspected, prompt work-up should be performed and discontinuation of the ICIs should be considered. Diagnosis must be done to differentiate between spinal cord compression, intra-cerebral metastases, and bacterial meningitis. In order to exclude bacterial meningitis in patients with fever or patients who are immuno-compromised, an urgent lumbar puncture is need. Electromyography and nerve conduction studies help diagnose peripheral neuropathies, and nerve biopsy helps diagnose vasculitis. Neurological history and physical examination may be helpful for diagnosis; therefore, early consultation with a specialized neurologist is necessary (85).

**Incidence**

The incidence of ICI-related neurotoxicity is reported as 1% in the clinical trial, but it is fatal (3). As it is directly related to the quality of life, patients may give up additional chemotherapy if they experience neurological sequelae. ICI-related neurotoxicity mostly occurs within 3 months of drug initiation. Patterns of neurotoxicity are different depending on the ICIs used (86). Neuromuscular junction dysfunction (myasthenia gravis), non-infectious encephalitis, and myelitis occur more commonly with PD-1/PD-L1 inhibitors than anti-CTLA-4 agents. In contrast, Guillain-Barré syndrome and non-infectious meningitis occur more commonly with anti-CTLA-4 agents. It has been reported that adverse effects are more common with ipilimumab–nivolumab combination therapy than with monotherapy (87). Although sufficient data are lacking, some studies have reported that progression-free and overall survival are much longer in patients with ICI-related neurotoxicity (87,88). The mechanism of neurotoxicity is still unknown, but it is presumed to be caused by sub-perineural edema and inflammation of endoneurial microvessels (89).

**Treatment strategies**

The treatment of choice is a systemic steroid. If the symptoms progress, systemic steroids should be started immediately (90). If steroid therapy has been initiated, the dose should be maintained until an observation of response. It should also be applied if there is a concern about the use of steroids due to other underlying diseases or factors. If respiratory muscles are involved, the intensive care unit and ventilator care may be necessary. In the absence of a steroid response, plasmapheresis, administration of intravenous immunoglobulin, and immune modulators, such as infliximab, mycophenolate, and cyclosporine, may be considered (87).

**Myasthenia gravis**

Myasthenia gravis is the most lethal form of ICI-related neurotoxicity. Unlike other ICI-related neurotoxicities, it occurs within a month of drug use (3). Myasthenia gravis is
frequently accompanied by myocarditis and myositis (91). Unlike general myasthenia gravis, the test for acetylcholinesterase receptor Ab is frequently negative in this form of myasthenia gravis (92). Myasthenia gravis may cause an emergency that requires intensive care unit (ICU) treatment. Approximately 20% of patients with myasthenia gravis die, and the fatality rate is increased when the respiratory muscles are affected. High dose corticosteroids, plasma exchange and/or intravenous immunoglobulins are considered in fatal cases (93).

**Cognitive disorders**
ICI-related neurotoxicity has been focused on acute patterns and diseases. However, ICIs therapy is also suspected of being involved in causing the various aspects of chronic neurotoxicity, including cognitive disorders, fatigue, and mood disorders. In preclinical animal studies, ICIs can pass through the blood-brain barrier (94). ICIs can also change microglial activation and the levels of cytokines and chemokines in the brain (95). This change has been mainly demonstrated in the hippocampus, the center of cognitive function. Cognitive function and mood disorders are important factors that are directly linked to quality of life; often, this toxicity is neglected. Thus, further research is needed regarding cognitive disorders, fatigue, and mood disorders (96).

**OCULAR SYSTEM**
Ocular toxicities are known to be rare irAEs, with less than 1% of occurrence (97). The most common ICI-related ocular toxicity is uveitis. Most cases are bilateral and appear as anterior uveitis or pan-uveitis (98). Ocular toxicities occur within 6 months of using ICIs. Anti-CTLA-4 agents showed a higher incidence and severity of ocular toxicity than PD-1/PD-L1 inhibitors. ICIs induce more ocular toxicities than cytotoxic chemotherapy regimens (99). ICI-related ocular toxicity occurs more often in melanoma than other solid cancers. This observation may be explained through the cross-reactivity between malignant melanoma cells and normal choroidal melanocytes (100). Uveitis, especially in Vogt-Koyanagi-Harada like uveitis, is suspected to be a marker for a favor treatment response (101). Several cases have been reported that led to permanent loss of vision. Therefore, ophthalmic evaluation should be considered immediately if symptoms, such as worsening vision, floaters, or conjunctival injection, are detected (102). Uveitis can be easily treated with topical steroids, but systemic steroids should be considered when severity is high.

**THORAX**

**Heart**

*Clinical presentation and diagnosis*
ICI-related cardiotoxicity is relatively rare. However, it is life-threatening and fatal (3). ICI-related cardiotoxicity includes myocarditis, arrhythmias, conduction disease, acute coronary syndrome, congestive heart failure, and pericardial disease. The most common ICI-related cardiotoxicity is myocarditis. Diagnosis is based on clinical symptoms, laboratory findings and image tool, such as cardiac enzymes (troponin and creatinine kinases), echocardiogram, and electrocardiogram (103). Several studies report the usefulness of cardiac magnetic resonance imaging, although it is still controversial (104). Endomyocardial biopsy may be helpful for diagnosis, but it is an invasive procedure (105). Histologically, CD8+ T-cell and CD68+ macrophage, but not B-cell, infiltration is observed (106). Many cases are
asymptomatic, and the clinician’s awareness about cardiotoxicity is low (107). Therefore, attention to cardiotoxicity and efforts in cardiovascular monitoring are needed (108).

**Incidence**
The incidence of ICI-related myocarditis is known to be 0.09%–2.4% (109,110). However, the fatality rate is approximately 27%–60%, making ICI-related myocarditis the most dangerous irAE (91,111). The incidence and fatality rates are higher in ICI combination therapy than in ICI monotherapy (110). For example, ipilimumab–nivolumab combination therapy reported a fatality rate of 60% in myocarditis. In addition, a combination trial of ICIs and antiangiogenic agents, such as vascular endothelial growth factor (tyrosine kinase) inhibitors, has recently attracted attention, so cardiotoxicity has been increasingly an issue of concern. The time of occurrence varies, but fatal myocarditis usually occurs within a month of the first cycle of ICI infusion (109).

**Treatment strategies**
Cardiotoxicity has a significantly higher mortality rate than other irAEs, and it is recommended that ICIs are discontinued if cardiotoxicity is suspected. Systemic steroids are recommended for initial therapy, and 1 g per day of intravenous therapy should be considered if hemodynamic impairments are present (104). In steroid-refractory myocarditis, mycophenolate mofetil or tacrolimus should be considered (35,112). Recently, antithymocyte globulin, abatacept (CTLA-4 agonist), and alemtuzumab (anti-CD52 Ab) have been used for the treatment of steroid-refractory myocarditis (113,114). If the left ventricular ejection fraction is less than 50%, angiotensin-converting-enzyme inhibitors may be useful (115). Unlike other side effects, the re-initiation of ICIs is reported to be extremely dangerous (116).

**Mechanism**
The mechanism of cardiotoxicity is unknown. The presumed mechanism is that the PD-L1 and CTLA-4 pathways have a cardioprotective mechanism (especially T-cell-mediated inflammation), and ICIs disrupt immune tolerance in the heart (117). This hypothesis is based on the observation that PD-L1 expression in cardiomyocytes is upregulated in cardiac disease or injury (14). Postmortem analysis in ICI-related fatal myocarditis cases showed an increase in cytotoxic T-cells and macrophages. Dilated cardiomyopathy or autoimmune myocarditis has been observed in PD-1 knockout mouse models (118,119). Moreover, severe myocarditis with cytotoxic T-lymphocyte infiltration has been reported in a CTLA-4 knockout mouse models (120). In contrast, some reports suggest that cardiotoxicity occurs because of shared Ags and epitopes among the heart, muscle, and tumor cells (109).

**Lung**

**Clinical presentation and diagnosis**
Symptoms involving the lungs are very diverse and nonspecific, and some patients do not experience respiratory symptoms (121). It is crucial to exclude infections in diagnosis; thus, bronchoscopy or bronchoalveolar lavage may be helpful for differential diagnosis. However, no specific histologic findings are available yet. In addition, chest imaging and computed tomography are essential for diagnosis and detection. ICI-related pneumonitis exhibits a variety of imaging patterns, such as organizing pneumonia, nonspecific interstitial pneumonia, hypersensitivity pneumonitis, acute interstitial pneumonia, acute respiratory distress syndrome, bronchiolitis, and radiation recall (122). The dominant radiologic pattern is organizing pneumonia.
Incidence
ICI-related pneumonitis is rarer than other irAEs, but it is the most fatal irAE associated with PD-1/PD-L1 inhibitor therapy. ICI-related pneumonitis accounts for 35% of deaths due to PD-1 / PD-L1 inhibitor monotherapy (3). The overall incidence rate of ICI-related pneumonitis observed in clinical trials with ICI monotherapy is 2.5%–5.0%, and that with ICI combination therapy ranges 7%–10% (121). As clinical trials target healthy patients who have no underlying lung disease or autoimmune disease, the incidence in real world data ranges from 7%–19% (123). Moreover, the incidence of ICI-related pneumonitis is higher in non-small cell lung cancer than in other tumors (124). Further, PD-1/PD-L1 inhibitors showed a higher incidence and severity of pulmonary toxicity than that shown by anti-CTLA-4 agents (15), and PD-1 inhibitors show a higher incidence and severity of pulmonary toxicity than do PD-L1 inhibitors (125). Underlying lung disease (interstitial lung disease, asthma, and chronic obstructive pulmonary disease) and prior thoracic radiation are considered risk factors for ICI-related pneumonitis (126,127). The mean duration of onset is approximately 3 months (128).

Treatment strategies
The framework of treatment is similar to drug-related hypersensitivity pneumonitis. The basis of treatment is ICI cessation, systemic steroids, and immunosuppressive medications (129). It has been reported that, if ICIs are restarted, ICI-related pneumonitis can recur in 20% of cases (130). Moreover, even after accomplishment of systemic steroid treatment and absence of retrying ICI therapy, some patients experience recurrent pneumonitis (131).

CONCLUSION
ICIs can cause a variety of unexpected side effects throughout the whole body. IrAEs are sometimes nonspecific or ambiguous, such as cardiotoxicity and endocrine toxicity. An important point in the treatment of irAEs is early detection and diagnosis. It should be noted that all new symptoms after ICI initiation could be irAEs. Regular checkups, such as thyroid function tests or cardiac enzymes, need to be performed. The basis of most irAE treatments is the use of systemic steroids. However, an immune modulator may be used in the absence of steroid response. Multidisciplinary treatments under the supervision of specialists are essential, because the symptoms and treatment of irAEs may involve multiple organs.

REFERENCES


